CNS Drug Discoveries: Depression Chapter
Topics: Drug Discovery, CNS/Neurology, Behavioral Health
|
Anti-addiction Therapies, 2006-2011 - The Pharmaceutical Industry’s Next Viagra?
Topics: Pharmaceuticals, Research & Development, CNS/Neurology, Behavioral Health
|
The 2007-2012 Outlook for Antidepressant Pharmaceuticals in the United States
Topics: Prescription Drugs, Behavioral Health
Regions: United States
|
The 2007-2012 Outlook for Psychotherapeutic Antidepressant Agents in the United States
Topics: Prescription Drugs, Behavioral Health
Regions: United States
|
Worldwide Psychotherapeutic Drug Market
Topics: Pharmaceuticals, Behavioral Health
Regions: Global
|
Residential Mental Health and Substance Abuse Facilities in the US
Topics: Facilities, Behavioral Health
Regions: United States
|
Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression Set to Drive Near-term Growth
Topics: Research & Development, Prescription Drugs, CNS/Neurology, Behavioral Health
|
Conference Documentation: Depression & Anxiety
Topics: Prescription Drugs, Behavioral Health
|
European Antidepressants Markets
Topics: Behavioral Health
Regions: Europe
|
The 2007-2012 World Outlook for Psychotherapeutic Antidepressant Agents
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
The 2007-2012 World Outlook for Psychotherapeutic Tranquilizing Agents Excluding Phenothiazine Derivatives
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
Stakeholder Insight: Major Depressive Disorder - Duloxetine - Fulfilling An Unmet Need?
Topics: Prescription Drugs, Behavioral Health
|
Pipeline Insight: Anxiety Disorders - A Decade of Declining Revenues
Topics: Behavioral Health
|
Residential Mental Retardation Facilities in the US
Topics: Behavioral Health
Regions: United States
|
Sleeper Diseases: Forecast and Assessment of Neglected Disease Market Opportunities
Topics: Diseases & Conditions, Respiratory/Pulmonary, Behavioral Health
|
Antidepressants
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
Residential Mental Retardation Facilities in the US - Industry Market Research Report
Topics: Facilities, Behavioral Health
Regions: United States
|
Impact of Generics on the Antidepressant Market
Topics: Pharmaceuticals, Generics Drugs, Prescription Drugs, Behavioral Health
|
Residential Mental Health and Substance Abuse Facilities in the US
Topics: Facilities, Behavioral Health
Regions: United States
|
Opportunities and Challenges in the Adult Attention-Deficit/Hyperactivity Disorder Market
Topics: Behavioral Health
|
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Topics: Prescription Drugs, CNS/Neurology, Behavioral Health
Regions: United States, Global
|
Residential Mental Retardation Facilities in the US
Topics: Facilities, Behavioral Health
Regions: United States
|
The World Market for Antidepressants, 2006
Topics: Prescription Drugs, Behavioral Health
|
Emotional and Behavioral Disorders in Children and Adolescents
Topics: Children, Teens (13-19), Behavioral Health
|
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
Topics: Behavioral Health
|
Biomedical Smart Report: Depression
Topics: Behavioral Health
|
Biomedical Smart Report: Anxiety
Topics: Behavioral Health
|
Residential Mental Retardation Facilities in the US
Topics: General Facilities, Behavioral Health
Regions: United States
|
The 2006-2011 World Outlook for Psychotherapeutic Antidepressant Agents
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
The 2006-2011 World Outlook for Psychotherapeutic Tranquilizing Agents Excluding Phenothiazine Derivatives
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
The 2006-2011 World Outlook for Psychotherapeutic Agents Excluding Tranquilizers and Antidepressants
Topics: Prescription Drugs, Behavioral Health
|
Opportunities in the Pharmacotherapy of Addiction
Topics: Behavioral Health
|
US Antidepressants 2004
Topics: Prescription Drugs, Behavioral Health
Regions: United States
|
Commercial Insight: Antipsychotics - From Blockbuster Brands to Billion Dollar Generics
Topics: Prescription Drugs, Behavioral Health
|
Stakeholder Insight: Patient Compliance in Psychiatry - From Patient Acquisition to Patient Retention
Topics: Behavioral Health
|
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
Topics: Behavioral Health
|
US - Residential Mental Health & Substance Abuse Facilities
Topics: Facilities, Behavioral Health
Regions: United States
|
U.S. Antipsychotic Medications Markets
Topics: Prescription Drugs, Behavioral Health
Regions: United States
|
Adult ADHD - Strattera Grows Up
Topics: Behavioral Health
|
Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity
Topics: Behavioral Health
|
US - Residential Mental Health & Substance Abuse Facilities
Topics: Facilities, Behavioral Health
Regions: United States
|
Stakeholder Insight: Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth
Topics: Behavioral Health
|
Commercial Insight: Antidepressants - Sliding SSRI Revenues Inevitable
Topics: Prescription Drugs, Behavioral Health
|
U.S. Markets for Addiction and Substance Abuse and Treatments
Topics: Behavioral Health
Regions: United States
|
Antidepressants: World Prescription Drug Markets
Topics: Prescription Drugs, Behavioral Health
Regions: Global
|
Pipeline Insight: Antipsychotics - Novel Antipsychotics Driving Market Evolution
Topics: Prescription Drugs, CNS/Neurology, Behavioral Health
|
Pharma Market Forecast: Antipsychotics to 2011
Topics: Prescription Drugs, Behavioral Health
|
Stress Management
Topics: Behavioral Health
|
Pipeline Insight: Depression - Novel therapies key to market penetration
Topics: Prescription Drugs, Behavioral Health
|
Rapid Cycling Bipolar Disorder: Another niche indication?
Topics: Behavioral Health
|
